STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF ASPIRIN AND CLOPIDOGREL IN DOSAGE FORM

(Kestabilan Kaedah KCPT-Indikator bagi Penentuan Serentak Asprin dan Clopidogrel Dalam Bentuk Dos)

Md. Gousuddin*, Pinaki Sengupta, Vijaya Datt Tripathi, Arindam Das

Faculty of Pharmacy,
Lincoln University College, 47301 Petaling Jaya, Selangor, Malaysia

*Corresponding author: Inamdarirfan09@gmail.com

Received: 13 June 2015; Accepted: 1 February 2016

Abstract
Stability-indicating High Performance Liquid Chromatographic (HPLC) method was developed for simultaneous Aspirin and Clopidogrel, using Phenomenex Gemini C-18, 5 µm column having 250mm x 4.6 mm i.d. in isocratic mode, with mobile phase containing buffer solution of 0.3% orthophosphoric acid : acetonitrile (65: 35, v/v). The flow rate was 1 ml/min and effluents were monitored at 266 nm. For linearity seven points calibration curve were obtained in a concentration range from 0.030 – 0.120 mg/ml for aspirin and 0.015 – 0.060 mg/ml for clopidogrel with correlation coefficient 0.9999. In the present study stability indicating HPLC method for the combination was tested by degrading the drugs together under various stress conditions like acid hydrolysis, base hydrolysis, oxidation, thermal and photolytic stress which is recommended by ICH guideline.

Keywords: reverse phase high performance liquid chromatography, stability indicating method, aspirin, clopidogrel

Introduction
Platelet aggregation and thrombus formation play a critical role in the initiation and development of key complications of acute coronary syndromes (ACSs). Antiplatelet therapy and antithrombotic therapy have been demonstrated to favorably modify clinical outcome, and recent trials of revascularization in ACSs have demonstrated a reduction in the frequency of major cardiac events [1 – 12]. Antiplatelet and anti-thrombin have synergistic actions that reduce the risk of spontaneous or revascularization, especially percutaneous coronary intervention (PCI)-related events. Yet, all effective antithrombotic agents also increase the risk of bleeding,

ISSN 1394 - 2506
especially bleeding that results from vascular accessor associated with surgery, including coronary artery bypass grafting (CABG). The Clopidogrel in unstable angina to prevent recurrent ischemic Events (CURE) trial demonstrated that the combination of clopidogrel and aspirin was superior to aspirin alone for patients hospitalized with non-ST-elevation ACSs.

Aspirin is chemically acetylsalicylic acid (Figure 1). Its molecular formula is C_9H_8O_4 having molecular weight 180 g/mole [14]. It is slightly soluble in water, freely soluble in alcohol, soluble in chloroform and ether, sparingly soluble in absolute ether. Aspirin, one of the first drugs to come into common usage, is still the most widely used drug in the world, is a non-steroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic and antipyretic activities.

![Figure 1. Chemical structure of aspirin](image)

Clopidogrel bisulfate, chemically it is (S - (a)(2 - chlorophenyl) - 6,7 - dihydrothieno (3,2-C) pyridine-5 (4H) acetic acid methyl ester sulphonate] (Figure 2). The empirical formula of clopidogrel bisulfate is C_{16}H_{16}ClNO_2S•H_2SO_4 and its molecular weight is 419.9 g/mole [14]. It is a white to off-white powder. It is practically insoluble in water at neutral pH but freely soluble at pH 1. It also dissolves freely in methanol, dissolves sparingly in methylene chloride and is practically insoluble in ethyl ether. It has a specific optical rotation of about +56°. The structural formula is as follows:

![Figure 2. Chemical Structure of clopidogrel](image)

The combination of clopidogrel with aspirin provides enhanced prevention of atherothrombotic events by blocking the platelet aggregation by both ways. (ADP pathway and collagen induced pathway) and it shows a synergistic antiplatelet action in controlling the ischemic events.

Literature reveals that various methods simultaneous determination of aspirin and clopidogrel in pharmaceutical formulation HPTLC [5 – 6]. Various publications are available regarding determination method of aspirin and clopidogrel but most of the methods are applicable to alone aspirin or clopidogrel in pharmaceutical dosage form or in biological fluids. Only three methods are reported for the simultaneous determination of aspirin and clopidogrel. One is semi-micro column HPLC-UV method for simultaneous determination of clopidogrel metabolite, aspirin and salicylic acid in rat plasma. Second is a spectrophotometric method, which is able to determine aspirin and clopidogrel in combine dosage form and third is simple high performance liquid chromatography, which applicable to routine quality control sample analysis. The separation is performed by high
performance liquid chromatography for reasons of robustness and familiarity of analysts with this technique. To our knowledge, no stability-indicating analytical method for the determination of aspirin and clopidogrel in combine dosage forms has been published.

In the present study stability indicating HPLC method for the combination was tested by degrading the drugs together under various stress conditions like acid hydrolysis, base hydrolysis, and oxidation, thermal and photolytic stress which is recommended by ICH guideline.

Materials and Methods
Pharmacopoeial grade standards of aspirin and clopidogrel bisulphate were provided by Blue Cross laboratory. A tablet containing 150 mg aspirin and 75 mg clopidogrel was commercially available. HPLC grade acetonitrile, methanol and water were obtained from Spectrochem Pvt. Ltd., Mumbai (India). Analytical grade hydrochloric acid, sodium hydroxide pellets, orthophosphoric acid and hydrogen peroxide solution (30 % v/v) were obtained from Ranbaxy Fine Chemical, New Delhi (India).

HPLC instrumentation and conditions
The chromatographic system used to perform development and validation of this assay method was comprised of (SHIMADZU, HPLC) with LC-20AT (VP series) pump, with software Spinchrom and UV-Visible detector SPD-20A (VP series). Chromatographic analysis was performed on a Phenomenex Luna C8 (250 mm 4.6 mm i.d., 5 µm particle size) column. The mobile phase was consisted of 0.3 % orthophosphoric acid (v/v) - acetonitrile (65:35, v/v). The flow rate of the mobile phase was adjusted to 1.0 ml/min and the injection volume was 20 µl. Detection was performed at 226 nm.

In the presence work, an analytical method based on LC using UV detection was developed and validated for assay determination of aspirin and clopidogrel in tablet formulation. The analytical conditions were selected, keeping in mind the different chemical nature of aspirin and clopidogrel. The development trials were taken by using the degraded sample of each component was done, by keeping them in various extreme conditions.

The column selection has been done on the basis of backpressure, resolution, peak shape, theoretical plates and day-to-day reproducibility of the retention time and resolution between aspirin and clopidogrel peak. After evaluating all these factors, C8 (2) (250 mm 4.6 mm i.d., 5 µm particle size) column was found to be giving satisfactory results. The selection of buffer based on chemical structure of both the drugs.

Preparation of stock solution for stress studies
The degradation samples were prepared by transferring powdered tablets, equivalent to 150 mg aspirin and 75 mg clopidogrel into a 250 ml round bottom flask. Then prepared samples were employed for acidic, alkaline and oxidant media and also for thermal and photolytic stress conditions. After the degradation treatments were completed, the stress content solutions were allowed to equilibrate to room temperature and diluted with mobile phase to attain 0.075 mg/ml of aspirin and 0.0375 mg/ml of clopidogrel concentration.

Results and Discussion
The acidic pH range was found suitable for solubility, resolution, stability, theoretical plates and peak shape of both components. Best results were obtained with 0.3 % orthophosphoric acid solution improved the peak shape of aspirin and clopidogrel. Finally, by fixing 0.3 % orthophosphoric acid (v/v) and mobile phase composition consisting of a mixture of 0.3% orthophosphoric acid (v/v) into ratio 65:35, v/v. Optimized mobile phase proportion was providing good resolution between aspirin and clopidogrel and also for degradation product which is generated during force degradation study. For the selection of organic constituent of mobile phase, acetonitrile was chosen to reduce the longer retention time and to attain good peak shape. Figure 1 and Figure 2 represent the Chromatograms of standard and test preparation respectively.
In order to determine whether the analytical method or assay were stability-indicating, aspirin and clopidogrel combine tablets were stressed under various conditions to conduct forced degradation studies. Regulatory guidance in ICH Q2A, Q2B, Q3B and FDA 21 CFR section 211 all require the development and validation of stability-indicating potency assays. Unfortunately, the current guidance documents do not indicate detailed degradation conditions in stress testing. However, the used forced degradation conditions, stress agent concentration and time of stress, were found to effect degradation and not complete degradation of active materials. The discovery of such conditions was based on development trial.

**Acidic condition**
Acidic degradation study was performed by heating the drug content in 1 N HCl (50 ml) at 80 °C for 1 hour and mixture was neutralized with 1 N NaOH solution. The drug content was found to be degrading up to 16.93 % in acidic condition. Clopidogrel was more susceptible to acid hydrolysis under experimental conditions. In all degradation conditions the drug degrades as observed by the decreased area in the peak of the drug when
compared with peak area of the same concentration of the undegraded drug, with giving one additional degradation peak at 9.02 min.

![Chromatogram of acidic forced degradation study](image)

Figure 3. Chromatogram of acidic forced degradation study

**Alkaline condition**
Alkaline degradation study was performed by heating the drug content in 1 N NaOH (50 ml) at 80 °C for 1 hour and mixture was neutralized with 1 N HCl solutions. In alkali degradation, it was found that around approximately 22 % of the drug was degraded (Figure 4). Aspirin was more susceptible to alkaline hydrolysis under experimental conditions. In all degradation conditions the drug degrades as observed by the decreased area in the peak of the drug when compared with peak area of the same concentration of the undegraded drug, with giving one additional degradation peak at 4.72 min.

![Chromatogram of alkali forced degradation study](image)

Figure 4. Chromatogram of alkali forced degradation study
Oxidative condition
Oxidation degradation study was performed by heating the drug content its initial concentration carried out in 1% v/v hydrogen peroxide no significant changes then will increase into 3% v/v hydrogen peroxide at 80 °C for 30 minutes. In oxidative degradation, it was found that approximately 15.84 % of drug was degraded (Figure 5).

Figure 5. Chromatogram of oxidative forced degradation study

Thermal condition
Thermal degraded samples wherever degradation possible from about 1% to 30%. Preferably, the following stress conditions are performed by exposing solid drug at 80 °C for 72 hours. Resultant chromatogram of thermal degradation study (Figure 6) indicates that aspirin is found to be slightly stable under thermal degradation condition. Only 7.0 % of drug content was degraded.

Figure 6. Chromatogram of thermal degradation study

Photolytic condition
Exposure of drug molecules may produce photolytic degraded products. The rate of photo degradation depends upon the
intensity of incident light and quantity of light absorbed by the drug molecule. Photolytic degradation is carried out by exposing the drug substance (in solid as well as in the solution form) or drug product to a combination of visible and UV light. Photolytic degradation study was performed by exposing the drug above specific photolytic condition. Drug content was found to be more stable than other stress condition stable in UV-light. Aspirin is stable under UV light compare to clopidogrel. (Figure 7).

![Figure 7. Chromatogram of UV-light degradation study](image)

**Linearity**

For linearity seven points calibration curve were obtained in a concentration range from 0.030 – 0.120 mg/ml for aspirin and 0.015 – 0.060 mg/ml for clopidogrel, respectively. The response of the drug was found to be linear in the investigation concentration range and the linear regression equation for aspirin was $y = 60026378.57x + 51410.11$ with correlation coefficient 0.9999 (Figure 8) and for clopidogrel was $y = 44544414.03x - 1890.29$ with correlation coefficient 0.9999 (Figure 9). Where $x$ is the concentration in mg/ml and $y$ is the peak area in absorbance unit.

![Figure 8. Linearity curve for aspirin](image)
Detection and Quantification Limit (LOD and LOQ)
The limit of detection and limit of quantification were evaluated by serial dilutions of aspirin and clopidogrel stock solution in order to obtain signal to noise ratio of 3:1 for LOD and 10:1 for LOQ. The LOD value for aspirin and clopidogrel were found to be 0.05 ppm and 0.15 ppm, respectively and the LOQ value 0.2 ppm and 0.3 ppm, respectively. Chromatogram of LOD study for aspirin and was illustrated in Figure 10.

Precision
Data obtain from precision experiments are given in Table 1 for intraday and interday precision study for both aspirin and clopidogrel. The RSD values for intraday precision study and interday precision study was < 2.0 % for aspirin and clopidogrel. It was confirmed that the developed method was precise for analysis. Results of precision in this study was summarized in the Table 1 below
Table 1. Results of precision study

| Set | Aspirin (% Assay) | Clopidogrel (% Assay) |
|-----|------------------|----------------------|
|     | Intraday (n = 6) | Interday (n = 6)    |
| 1   | 99.1             | 100.2                |
| 2   | 100.0            | 99.9                 |
| 3   | 99.6             | 100.5                |
| 4   | 99.5             | 100.3                |
| 5   | 100.3            | 101.0                |
| 6   | 99.1             | 100.8                |
| Mean|                 |                      |
| % RSD| 0.48             | 0.53                 |

Accuracy
Recovery of aspirin and clopidogrel were determined at three different concentration levels. The mean recovery for aspirin was 99.12 – 99.83% and 98.20 – 100.35 % for clopidogrel (Table 2). The result indicating that the method was accurate.

Table 2. Results of accuracy study

| Level (%) | Amount Added Concentration (mg/ml) | Amount Found Concentration (mg/ml) | Recoverya (%) | RSDa (%) |
|-----------|-----------------------------------|-----------------------------------|---------------|----------|
| Aspirin   |                                   |                                   |               |          |
| 50        | 0.03751                           | 0.03721                           | 99.22         | 0.07     |
| 100       | 0.07497                           | 0.07432                           | 98.12         | 0.23     |
| 150       | 0.11250                           | 0.11232                           | 99.83         | 0.05     |
| Clopidogrel|                                   |                                   |               |          |
| 50        | 0.01874                           | 0.01840                           | 98.20         | 0.19     |
| 100       | 0.03748                           | 0.03695                           | 98.59         | 0.14     |
| 150       | 0.05627                           | 0.05647                           | 100.35        | 0.24     |

Robustness
The result of robustness study of the developed assay method was established in Table 3 and Table 4, respectively. The result had shown that during all variance conditions, assay value of the test preparation solution was not affected and it was in accordance with that of actual. System suitability parameters were also found satisfactory hence the analytical method would be concluded as robust method.
Table 3. Evaluation data of robustness study of aspirin

| Robust Conditions | % Assay | System Suitability Parameters |
|-------------------|---------|------------------------------|
|                   |         | Theoretical | Asymmetry | % RSD |
| Flow 0.9 ml/min   | 100.5   | 6460         | 1.05      | 0.22  |
| Flow 1.1 ml/min   | 100.3   | 5661         | 1.05      | 0.09  |
| 0.28 % H₃PO₄-ACN (65:35, v/v) | 100.0 | 6117         | 1.00      | 0.40  |
| 0.32 % H₃PO₄-ACN (65:35, v/v) | 99.7   | 5588         | 1.02      | 0.30  |
| 0.3% H₃PO₄-ACN (63:37,v/v)  | 100.2 | 5475         | 1.12      | 0.19  |
| 0.3% H₃PO₄-ACN (67:33,v/v)  | 100.1 | 5838         | 1.04      | 0.20  |
| Column change (different lot) | 100.4 | 5425         | 1.05      | 0.34  |

Table 4. Evaluation data of robustness study for clopidogrel

| Robust Conditions | % Assay | System Suitability Parameters | Resolution |
|-------------------|---------|--------------------------------|------------|
|                   |         | Theoretical | Asymmetry | % RSD |
| Flow 0.9 ml/min   | 98.5    | 6975         | 1.07      | 0.67  | 5.75  |
| Flow 1.1 ml/min   | 100.0   | 5992         | 1.06      | 0.39  | 5.14  |
| 0.28 % H₃PO₄-ACN (65:35,v/v) | 98.8 | 6899         | 1.03      | 1.03  | 6.35  |
| 0.32 % H₃PO₄-ACN (65:35,v/v) | 99.2   | 6113         | 1.03      | 0.69  | 5.6   |
| 0.3% H₃PO₄-ACN (63:37,v/v)  | 99.5   | 5850         | 1.11      | 0.70  | 4.31  |
| 0.3% H₃PO₄-ACN (67:33,v/v)  | 99.0   | 6185         | 1.04      | 0.30  | 5.71  |
| Column change (different lot) | 100.0 | 5996         | 1.04      | 0.25  | 4.97  |

Conclusion

The method was validated for all validation parameters as per ICH guidelines. The linearity range for aspirin and clopidogrel was 0.030 – 0.120 mg/ml for aspirin and 0.015 – 0.060 mg/ml for clopidogrel with correlation coefficient 0.9999. The % RSD for intra-day precision was < 2%. The developed and validated stability indication HPLC method is found to be linear, accurate, precise, specific and robust, confirming the stability indicating method for the simultaneous estimation of aspirin and clopidogrel.

References

1. Trialists’ Collaboration, A. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *British Medical Journal*, 324(7329): 71 – 86.
2. Kong, D. F., Califf, R. M., Miller, D. P., Moliterno, D. J., White, H. D., Harrington, R. A. and Topol, E. J. (1998). Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. *Circulation*, 98(25): 2829 – 2835.
3. Boersma, E., Harrington, R. A., Moliterno, D. J., White, H., Théroux, P., Van de Werf, F. & Simoons, M. L. (2002). Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. *The Lancet*, 359 (9302): 189 – 198.
4. Yusuf, S., Zhao, F., Mehta, S. R., Chrolavicius, S., Tognoni, G. and Fox, K. K. (2001). Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal Medicine, 345(7): 494 –502.

5. Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S. and Natarajan, M. K. (2001). Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. The Lancet, 358 (9281): 527 – 533.

6. PURSUIT Trial Investigators. (1998). Inhibition of platelet glucoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrin therapy. New England Journal Medicine, 339: 436 – 443.

7. PRISM Study Investigators. (1998). A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New England Journal Medicine, 338 (21): 1498 – 505.

8. GUSTO IV-ACS Investigators. (2001). Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. The Lancet, 357(9272): 1915 –1924.

9. Ragmin, F. (1999). Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. The Lancet, 354(9180): 708 – 715.

10. Wallentin, L., Lagerqvist, B., Husted, S., Kontny, F., Ståhle, E. and Swahn, E. (2000). Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. The Lancet, 356(9223): 9 –16.

11. Cannon, C. P., Weintraub, W. S., Demopoulos, L. A., Vicari, R., Frey, M. J., Lakris, N. and Braunwald, E. (2001). Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. New England Journal of Medicine, 344 (25): 1879 –1887.

12. Berkowitz, S. D., Granger, C. B., Pieper, K. S., Lee, K. L., Gore, J. M., Simoons, M. and Califf, R. M. (1997). Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. Circulation, 95 (11): 2508 – 2516.